Nvax stock price forecast the nvax stock price forecast points to

The nvax stock price forecast points to possible range-bound action as risk appetite remains muted. NVAX’s beta above 1.5 makes it sensitive to broader market swings, and moving averages at $4.80 are being watched by traders for breakout confirmation. Due to its reliance on Sanofi's sales forecasts for certain components, Novavax continues to withhold its full-year revenue guidance. However, the company has raised its adjusted revenue framework and now expects to generate between $1 billion and $1.05 billion, implying an increase from the prior projection of $0.98-$1.03 billion. This revision is largely due to the receipt of $20 million for cost reimbursement from Sanofi for a post-marketing commitment (PMC) requested by the FDA on Nuvaxovid later this year. The company is now concentrating on bringing its vaccine candidates to market via strategic partnerships. Consequently, it granted the rights to its only commercial product, Nuvaxovid, to Sanofi in a deal worth up to $1.2 billion. Retail forums amplify nvax stock price forecast speculation, with sentiment indicators showing a shift toward moderate optimism after recent insider buying reports.